https://www.selleckchem.com/pr....oducts/guanosine-5-m
The humanized anti-CGRP monoclonal antibody eptinezumab has been evaluated in five large-scale clinical trials conducted in patients with migraine. This integrated analysis was conducted to evaluate the comprehensive safety and tolerability of eptinezumab in patients with migraine across these studies. Data were pooled from four randomized, double-blind, placebo-controlled studies and the first year of one open-label study. The pooled population comprised 2867 adults with migraine eptinezumab, n = 2076 (4
Like
Comment
Share
